New pill for inflammation takes first step in human safety trial
NCT ID NCT07029568
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new oral medicine, NNC0705-0001, in 116 healthy adults to see if it is safe and how the body handles it. The drug is being developed to treat chronic inflammation, which can lead to heart and metabolic diseases. Participants received either the drug or a placebo, and the study looked at side effects and drug levels in the blood over about 35-41 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON - location Groningen
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Aging kidneys under the microscope: could a simple test predict failure?
- Could a new pill quiet chronic pain? early trial puts it to the test
- Could your gut bacteria hold the key to protecting your kidneys?
- Brain waves under pressure: can light uncover the signature of mental work?